Women Who Use Cannabis Are More Likely To Have Satisfying Orgasms, Study Reveals

Women Who Use Cannabis Are More Likely To Have Satisfying Orgasms, Study Reveals

Women who consume cannabis before sex have better orgasms than those who do not, according to new data.

As the legalization movement continues to expand, more people are coming forward with questions and sharing personal experiences regarding how cannabis affects sex. Cannabis lubes are a hot item now and there are strains of flower said to increase arousal. While there is a plethora of anecdotal evidence out there regarding the ways that cannabis can be used to enhance sexual activity, the scientific research is limited.

One team of researchers exploring the relationship between cannabis and sex aims to contribute clinical findings to demystify how cannabis affects different sexual functions, in women specifically, like sex drive, arousal, orgasm, and overall satisfaction.

Inspired by talking to the patients who come to her practice, Becky K. Lynn, MD, is one of the main designers of the newly published study which determined that consuming cannabis before sexual activity can enhance pleasure and satisfaction with orgasms.

“My interest in this realm came from the many patients that I see in my clinic who have confided in me that using marijuana treats their sexual problems,” Lynn said to Weedmaps.

Aiming to examine how women interpret a sexual experience when cannabis has been consumed before hand, this study analyzes first-hand reports about:

  • Overall sexual satisfaction
  • Sex drive
  • Orgasm
  • Dyspareunia (pain during sex)
  • Lubrication

“I have seen it used in women with chronic pain disorders that lead to painful sex, women who experience difficulty with orgasm or an inability to orgasm, and women who use it to improve their libido, which may not match their partner’s libido,” said Lynn

The Study

According to researchers, the specific goal of this cross-sectional study, titled “The Relationship between Marijuana Use Prior to Sex and Sexual Function in Women,” is to “evaluate women’s perceptions of the effect of marijuana use before sexual activity.”

Published online March 1, 2019 in Sexual Medicine, the data was analyzed and interpreted by:

  • Becky K. Lynn, MD
  • Julia D. Lopez, PhD, MPH, LCSW
  • Collin Miller, MSW
  • Judy Thompson, RN, CCRC
  • E. Cristian Campian, MD, PhD

Spanning an 11 month period from March 2016 to February 2017, the study’s sample group consisted of female patients from one obstetrics and gynecology office. The patients were asked to complete an anonymous sexual health survey during their visit to the doctor’s office.

Once a participant was finished with the questionnaire, she would put it directly into a box secured with a lock, and the data was reviewed at a later time.

The Data

There were 373 women in total who completed the questionnaire during their visit to the doctor over the 11 month period in which the study took place. The demographic information shows that most of the study participants were about the same age, were white and identified as heterosexual.

Upon reviewing the information, the sample group of 373 women was divided into two main groups — non-cannabis users and cannabis users.

There were 197 women in the ‘non-cannabis user’ group (52.8 percent) and 176 women were assigned to the ‘cannabis-user’ group. Being assigned to the ‘cannabis-user’ group did not necessarily mean that she consumed before partaking in sexual activities.

According to the data, 34 percent of the ‘cannabis-users’ (127 women) responded yes to using cannabis before sexual activity, while 13.1 percent (49 women) of the ‘cannabis-users’ did not consume before sex, but did at other times.

Of the 127 women who used cannabis before participating in a sexual activity, 2.13 percent reported that they have more satisfying orgasms than those who did not use cannabis. Participants who reported using cannabis frequently, but not necessarily before sex, were 2.10 times more likely to respond yes to having satisfactory orgasms than those who reportedly used cannabis infrequently.

The study states that “most women reported an increases in sex drive, an improvement in orgasm, a decrease in pain, but no change in lubrication.”

The Findings

According to the study’s authors, there were two main outcomes observed:

  1. “Satisfaction in the sexual domains of drive, orgasm, lubrication, dyspareunia, and overall sexual experience.”
  2. “The effect of the frequency of marijuana use on satisfaction.”

Timing was an important factor with the women who reported using cannabis before sex. The proper timing between cannabis consumption and sex was crucial for a “positive effect on orgasm.”

Contributing clinical examples to what we understand about the relationship between cannabis and sex, this study concludes that cannabis can have a positive impact on a woman’s sex life, and more research should be completed on the topic.

Photo Courtesy of Valeria Boltneva from Pexels

Marijuana Research Is Exploding In The Age Of Legalization, New Study Finds

Marijuana Research Is Exploding In The Age Of Legalization, New Study Finds

Researchers are now churning out thousands of studies on marijuana each year. And you can expect that stream of science to keep flowing as more places enact legalization, a new review predicts.

To get a better understanding of how the scientific community has responded to the cannabis reform movement, a team based in Israel used online research databases like PubMed and Web of Science to search for marijuana-related studies from 2000 to 2017.

Research on cannabis has rapidly accelerated in recent years, far outpacing the growth in scientific research as a whole, the new study, which was published this month in the journal Population Health Management, found.

While the overall number of scientific publications per year on PubMed increased 2.5 times during the years in review, the number of publications that examine cannabis increased 4.5 times, from 620 to 2388. The number of studies focused on medical cannabis increased nine times over the same period, from 82 in 2000 to 742 in 2017.

Population Health Management

“The results of the present study demonstrate an ongoing increase in the number of publications related to cannabis in general and to medical cannabis in particular,” the researchers wrote. “The spike in medical publications on medical cannabis that began in 2013 is impressive and encouraging.”

The team went on to categorize each study by medical field.

Population Health Management

Cannabis studies that fell into the neurology realm—which would encompass research looking at how cannabinoids affect conditions like epilepsy, for instance—were the most common and experienced the steadiest growth. Oncological studies on marijuana and cancer were the second most common, followed by psychiatric cannabis studies.

Where are the studies coming from?

Though marijuana remains federally prohibited in the United States, the country also pumps out the most cannabis research globally. Sixty-six percent of the studies under review from 2000 to 2017 originated in the U.S. The second biggest source of marijuana research is Canada, which produced 7.5 percent of the studies in review.

The authors of the new paper noted that cannabis research was stunted following the passage of prohibitionist policies in the 70s. And the recent uptick seems to correspond with state-level legalization efforts.

“The absence of an increase in publications on cannabis until recent years would appear to be related to the United Nations Single Convention that prohibited the use of cannabis for recreational purposes and had broad support in most of the developed countries,” the researchers wrote.

“It is noteworthy that the significant growth in the number of publications on medical cannabis since 2013 parallels legislation permitting the use of recreational cannabis in the states of Washington and Colorado in 2012 and in Alaska and Oregon in 2014, and subsequently in many other countries around the world.”

The team was heartened by the emerging trends in marijuana research, arguing that such a proliferation “should provide data, support, and confidence and should open new horizons for treatment of patients.”

And what’s more, the decision by the new study’s authors to categorize previous science based on medical field “can help direct researchers and policy makers to fields in which data are scant or not available at all,” they wrote.

See the original article published on Marijuana Moment below:

Marijuana Research Is Exploding In The Age Of Legalization, New Study Finds

Senate Amendment Requires Feds To Study Marijuana Legalization’s Impact

Senate Amendment Requires Feds To Study Marijuana Legalization’s Impact

The U.S. Senate may consider an amendment next week that would require federal agencies to conduct a study on how marijuana legalization is impacting states that have adopted it.

The measure, filed on Thursday by Sen. Robert Menendez (D-NJ), would direct the Departments of Justice, Labor and Health and Human Services to contract with the National Academy of Sciences for a 10-year examination of “monetary amounts generated” by legal cannabis tax revenue, as well as “rates of medicinal use” and “rates of overdoses with opioids and other painkillers” in states with some form of legalization, among other datapoints.

“The need for Congress to pull its head from the sand regarding the implications of functional regulated marijuana markets is dire,” Justin Strekal, political director for NORML, told Marijuana Moment. “No senator can intellectually justify remaining willfully ignorant to the results of successful state-legal programs and the National Academy of Sciences can prove to be the neutral arbitrator in assessing the real world impact that is happening in 31 medical or adult-use states throughout the country.”

The Senate amendment’s text is similar to standalone House legislation that Reps. Tulsi Gabbard (D-HI, Carlos Curbelo (R-FL) and others filed last month.

Watch Congresswoman Tulsi Gabbard And Other Federal Reps File New Marijuana Bill

The senator is seeking to attach the language to a bill to fund parts of the federal government, including the Departments of Defense, Labor, Education and Health and Human Services, for Fiscal Year 2019. The legislation has been on the floor this week, with consideration expected to resume on Monday.

Menendez’s Senate proposal isn’t identical to Gabbard’s House bill, as it leaves out directives from the earlier legislation for federal agencies to study legalization’s impact on criminal justice and employment. Advocates said that those sections weren’t germane to the title of the appropriations bill the senator is seeking to amend, and therefore had to be excluded.

Separately from the amendment, the senator plans to file a standalone companion bill containing the full text of the Marijuana Data Collection Act, his communications director, Patricia Enright, told Marijuana Moment in an email.

“Senator Menendez believes that as more and more states, including New Jersey, legalize medical or recreational marijuana, it makes good sense that we provide for independent, science-based research and analysis of current legalization policies and their impacts on communities,” she said. “If federal policy-makers are going to be a productive part of the conversation moving forward, it’s important that they be informed by objective, evidence-based data.”

For now, it is not clear if the Menendez amendment will be debated or receive a vote on the Senate floor before the body finalizes the spending legislation.

See the original article published on Marijuana Moment below:

Senate Amendment Requires Feds To Study Marijuana Legalization’s Impact

Study Indicates Cannabis May Battle Alzheimer’s Disease

Study Indicates Cannabis May Battle Alzheimer’s Disease

Studies have shown that the cannabinoids found in marijuana play beneficial roles in the treatment of many debilitating medical conditions affecting the human brain. For example, a recently published study confirmed previous indications that cannabinoids help to shrink aggressive brain tumors. Another recent study linked cannabis use with increased chances of surviving a brain injury. Now, another study has confirmed that cannabis may also play a role in the treatment of the degenerative brain disease known as Alzheimer’s.

Alzheimer disease, a form of dementia that most commonly strikes people aged 65 and older, is a bit of a medical mystery. Although there is no reason known to cause the onset, nor to cure it, a study from a team in South Florida, lead by neuroscientist Chuanhai Cao, PhD, found that low levels of delta-9-tetrahydrocannabinol (THC), the psychoactive cannabinoid in marijuana, may “slow or even halt the progression of Alzheimer’s disease.”

The study, published in the Journal of Alzheimer’s Disease earlier this year, was titled “The Potential Therapeutic Effects of THC on Alzheimer’s Disease.” The study summary stated, “These sets of data strongly suggest that THC could be a potential therapeutic treatment option for Alzheimer’s disease through multiple functions and pathways.”

There are many hypotheses about what causes the progression of the condition. The most commonly accepted, lists plaques and tangles in the brain as the culprits causing the degeneration and death of brain cells, which results in such symptoms as memory loss. The Alzheimer’s Association defines plaques as, “deposits of a protein fragment, called beta-amyloid, that build up in the spaces between nerve cells.” Tangles are defined as, “twisted fibers of another protein called tau that build up inside cells.” It is normal for plaques and tangles to develop in an aging brain, but the development significantly increases, for a reason unknown, in people suffering from Alzheimer’s.

In this particular study, the cells tested were outside the body in an artificial cultural medium, using a method known as in vitro. The small amount of THC that was introduced to these cells was able to reduce the the build up of beta-amyloid and clear debris in the cells. If THC is able to reduce the build up of plaques, which stimulate the disease in the brain, it will likely be able to prevent or slow the progression of the disease when introduced inside the human body. The study also found that the introduction of THC increased the function of specialized subunits within cells known as mitochondria. Mitochondria play important roles in the life-cycle, growth, and death of cells. This demonstrates the potential that THC may have to reduce or possibly prevent the degeneration and death of the brain cells in the first place.

Lead author, Cao told USF Health, “THC is known to be a potent antioxidant with neuroprotective properties, but this is the first report that the compound directly affects Alzheimer’s pathology by decreasing amyloid beta levels, inhibiting its aggregation, and enhancing mitochondrial function.” He added, “Decreased levels of amyloid beta means less aggregation, which may protect against the progression of Alzheimer’s disease. Since THC is a natural and relatively safe amyloid inhibitor, THC or its analogs may help us develop an effective treatment in the future.”

When asked about the study, authors confirmed that potential benefits of using THC to treat Alzheimer’s far outweigh the risks, as no toxicity was observed. Although THC is associated with memory impairment, such a minimal quantity used for this study is no worse for a patient than the leading pharmaceuticals most commonly used to treat this disease.

More research must be done on this subject to confirm the findings with one-hundred percent confidence, but this study is a positive indication that the use of cannabis to treat degenerative brain diseases should be explored.

photo credit: Rocky Mountain Oils

Study Shows Marijuana Does Not Lower IQ

Study Shows Marijuana Does Not Lower IQ

A recent UK-based study says that there is no connection between non-habitual teen cannabis use and IQ. The was study conducted on 2,612 children born in the Bristol area of the United Kingdom between 1991 and 1992. Each child’s IQ was tested at the age of 8, then again at the age of 15. Each student at the age of 15 was also surveyed on their use of cannabis for this study.

Although there seemed to be correlation of lower test scores to cannabis use, the correlation was also tied to use of alcohol, tobacco, drugs, and other risky teen behaviors. After these factors were taken into account, researchers found that there was direct correlation between cannabis use and IQ. However, teens who used marijuana heavily did show measurable signs of cognitive damage. This group of heavy users showed a 3% drop in test scores as the result of using cannabis at least 50 times by the age of 15.

“People often believe that using cannabis can be very damaging to intellectual ability in the long-term, but it is extremely difficult to separate the direct effects of cannabis from other potential explanations,” researcher Claire Mokrysz explained. She went on to say that, “The belief that cannabis is particularly harmful may detract focus from and awareness of other potentially harmful behaviours.”

It may come surprising (or not) that alcohol use was found to be strongly associated with IQ decline, but no other factors were found to be predictive of IQ change. This study comes as a significant contradiction to many American studies which try to tie the drug to memory loss or long-term impaired cognition. As recent as 2012, a study by Duke University reported a link between heavy marijuana use and lower IQ scores. The study came under heavy fire by researchers who pointed out significant flaws in their methodology; not surprising considering that Duke is located in the heart of tobacco country. The study was discredited shortly after it’s publication.

With many areas of the world inching toward legalization, proper studies have a tremendous impact on public perception of cannabis. While use is restricted to adults, the prospect of losing brain cells is no less a worry to anyone using cannabis. This new study’s findings may help to curb fears of losing a few IQ points from smoking a joint. It will be presented at the European College of Neuropsychopharmacology next March.

Photo Credit: Colorlines.com

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!